

To: De Jong, Geert G SI-HE/2 <geert.dejong@shell.com>; Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>; Tsai, Shan SP SHLOIL-SHLOIL-HE <Shan.Tsai@shell.com>; Granville, Geoffrey C SCAN-HETS <Geoffrey.Granville@shell.ca>; Veenstra, Gauke GE SC-CHSE-GV <gauke.veenstra@shell.com>; Steup, David R SOPUS <DRSteup@ShellOPUS.com>
From: Cagen, Stuart Z SCC </O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=SC724012>
Cc:
Bcc:
Received Date: 2003-06-26 00:48:02 GMT
Subject: RE: Benzene Epidemiology STUDIES

Geert:

Thanks. How about CEFIC ?

Regards,

Stuart

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: De Jong, Geert G SI-HE/2
Sent: Wednesday, June 25, 2003 2:53 PM
To: Cagen, Stuart Z SCC; Clegg, Patsy M SCC-CHSE-PC; Tsai, Shan SP SHLOIL-SHLOIL-HE; Granville, Geoffrey C SCAN-HETS; Veenstra, Gauke GE SC-CHSE-GV; Steup, David R SOPUS
Subject: RE: Benzene Epidemiology STUDIES

Stuart,

Concawe will conduct a data consistency review of 4 cohort studies including Health Watch. See attached.
Best regards,

Geert de Jong
Senior Health Adviser
Shell International B.V.
PO Box 162, 2501 AN The Hague, The Netherlands

Tel: +31 70 377 2516 Fax: +31 70 377 2840 Other Tel: +31 6 55 124 123 (mobile)
Email: geert.dejong@shell.com
Internet: <http://www.shell.com>

-----Original Message-----

From: Cagen, Stuart Z SCC

Sent: 18 June 2003 19:06

To: Clegg, Patsy M SCC-CHSE-PC; Tsai, Shan SP SHLOIL-SHLOIL-HE; De Jong,

Geert G SI-HE/2; Granville, Geoffrey C SCAN-HETS; Veenstra, Gauke GE

SC-CHSE-GV; Steup, David R SOPUS

Subject: Benzene Epidemiology STUDIES

ALL, but particularly, Geert and Gauke:

I would like to be clear on where things currently stand regarding industry sponsored benzene epidemiology work. Here in the US there is the Shanghai Health study, but I am only getting fragments of information regarding CONCAWE or CEFIC sponsored work regarding a reassessment of exposure estimation for prior UK, Canadian and Australian studies and/or a meta-analysis of these studies. Are these under consideration ? underway ? Is there Shell sponsorship ?

Thanks

Stuart

Stuart Cagen

Shell Chemical LP

One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987

Email: stuart.cagen@shell.com

Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: Tsai, Shan SP SHLOIL-SHLOIL-HE

Sent: Wednesday, June 18, 2003 8:40 AM

To: Hommes, Kees CW SI-HE/2; De Jong, Geert G SI-HE/2

Cc: Cagen, Stuart Z SCC; Clegg, Patsy M SCC-CHSE-PC; Clarke-Sturman,

Anthony J SIPC-OMF/32; De Jong, Geert G SI-HE/2; Granville, Geoffrey C

SCAN-HETS; Ransdell, Jerry D SCC; Steup, David R SOPUS; Weidel, Rick R

SIPC-OXXS; Veenstra, Gauke GE SC-CHSE-GV

Subject: RE: Potential Benzene Epidemiology Study

Geert,

I would support a meta-analysis of similar studies from other existing benzene cohorts (e.g., Dow, Monsanto, Solusia) to increase the statistical power and stability of the point estimate. Although it may seem to be relatively straight forward, it would take time to accomplish this (up to 2 years). I still believe it is critically important to get this paper published and should try one more time to another peer reviewed journal. The journal I would suggest is "Regulatory Toxicology and Pharmacology", which would publish negative studies if they are relevant to regulatory issues. A description of the Journal is included - "The journal presents articles concerned with regulatory decisions and with the interpretation of scientific knowledge as influencing regulatory decisions. It is addressed to an International readership of scientists, program managers, research directors, attorneys, and business professionals." Even this journal declines to publish this article, we have nothing to loose. The web-site for this journal is as follow:

<http://www.elsevier.com/locate/issn/0273-2300>

Regards,
Shan

Shan P. Tsai
Manager, Epidemiology
Shell Health Services
Shell Oil Company
P O Box 2463, Houston, TX 77252-2463, United States of America

Tel: +1-713-241-6078
Fax: +1-713-241-5875
Email: shan.tsai@shell.com
Internet: <http://www.shell.com>
